China's Zai Lab In-Licenses Two Sanofi Respiratory Drugs
This article was originally published in PharmAsia News
Executive Summary
Zai Lab has signed an agreement with Sanofi to in-license two of the France-based company's drugs to develop as treatments for chronic respiratory diseases.